CN102228682A - Medicinal composition for treating increased blood viscosity and blood supply insufficiency of brain tissues - Google Patents
Medicinal composition for treating increased blood viscosity and blood supply insufficiency of brain tissues Download PDFInfo
- Publication number
- CN102228682A CN102228682A CN2011101584514A CN201110158451A CN102228682A CN 102228682 A CN102228682 A CN 102228682A CN 2011101584514 A CN2011101584514 A CN 2011101584514A CN 201110158451 A CN201110158451 A CN 201110158451A CN 102228682 A CN102228682 A CN 102228682A
- Authority
- CN
- China
- Prior art keywords
- glucose
- intravenous fluid
- medicinal composition
- blood
- human insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicinal composition for treating increased blood viscosity and blood supply insufficiency of brain tissues, and relates to a medicinal preparation. The medicinal composition is characterized in that: a glucose intravenous injection and a biosynthetic human insulin intravenous injection are prepared into an intravenous injection in the ratio that 1,000ml of the glucose intravenous injection with sugar content of 10 percent is mixed with 8-12 IU (International Unit) of the biosynthetic human insulin intravenous injection. In the medicinal composition, the two common medicaments are combined for use, so that the two diseases of increased blood viscosity and blood supply insufficiency of brain tissues can be treated. The medicinal composition has the advantages of no adverse effect, no side effect, safety and reliability for a human body; and since the structure of the biosynthetic human insulin intravenous injection is completely same as the structure of insulin secreted in the human body, the medicinal composition does not have anaphylactic response and can be used safely.
Description
Technical field
The present invention relates to pharmaceutical preparation, particularly relate to and treat that blood viscosity increases, the pharmaceutical composition of cerebral tissue blood supply insufficiency.
Background technology
Hyperlipidemia medically is being high thickness mass formed by blood stasis, and middle-aged and elderly people is easily suffered from.Hyperlipidemia has gently, in, the branch of weight.The many genus of general slight hyperlipidemia are physiological, often cause because of reasons such as hyperhidrosis, dehydration or hypoposias.In, severe hyperlipidemia patient is many with hyperlipidemia, packed cell volume increases makes slow blood flow easily organize blood stasis and anoxia, symptoms of cerebral ischemia such as giddy, dizzy, tinnitus, numbness of hands and feet appear in the patient, disturbance of consciousness etc. also can take place in coronary insufficiency symptom such as nervous, uncomfortable in chest.
Cerebral blood supply insufficiency is meant that a certain partial blood supply of human brain is not enough and causes the obstacle of brain function.The cause of disease of cerebral blood supply insufficiency is relevant with cerebral arteriosclerosis usually.Cerebral blood supply insufficiency can cause the multiple symptom of body, and insomnia is wherein apparent in view a kind of.
Current medical science increases the treatment blood viscosity, and the cerebral tissue blood supply insufficiency has various technical schemes, and the drug patent application part that relates to is a lot, and the treatment blood viscosity increases relevant have 28, and what the treatment cerebral blood supply insufficiency was relevant has 86.Yet, still do not have and can treat blood viscosity and increase, can treat the application part of the pharmaceutical composition of cerebral tissue blood supply insufficiency again.
Summary of the invention
The object of the present invention is to provide and a kind ofly treat that blood viscosity increases, the pharmaceutical composition of cerebral tissue blood supply insufficiency, can utilize existing types of drugs to be human health service better.
In existing medicine, the indication or the purposes of glucose intravenous fluid are: (1) replenishes physical ability and body fluid: be used for hypoalimentation or a large amount of body fluid that a variety of causes causes and lose (as vomiting, diarrhoea etc.), full intravenous nutrition, the hungry property ketosis of Hunger; (2) hypoglycemia; (3) hyperpotassemia; (4) hyperosmotic solution is as the tissue dewatering agent; (5) preparation peritoneal dialysis solution; (6) pharmaceutical diluents; (7) glucose tolerance test; (8) use for preparation GIK (polarized solution) liquid.The biosynthetic human insulin intravenous fluid then is used for the treatment of diabetes, for the treatment of stabilisation originally of diabetics, especially for the diabetes emergency case.
The inventor notices: glucose and insulin are intravital two kinds of interactional materials.Glucose derives from the starch in the food, and the effect through ptyalin is decomposed into maltose, is decomposed into glucose by intestinal absorption by the maltase in the saliva again, becomes substance in vivo.Glucose enters the islet cells of body internal stimulus pancreas, secretes the insulin of respective numbers, to each tissue of whole body and organ cell's Insulin receptor INSR, through the phosphorylation of tyrosine, regulates glucose and enters cell catabolism.Because the substrate difference of each cell is converted into different materials for whole body each tissue and organ utilization.
Discover that hospital generally gives patient treatment with single glucose intravenous fluid at present, this biochemistry rule with intravital glucose and insulin does not conform to.Import a large amount of glucose intravenous fluids to the patient in the short period of time, owing to the islet cells of pancreas can not secreted a large amount of insulins in the short period of time blood glucose is increased.Kidney is at the filtering blood that does not stop, because glucose belongs to micromolecule, after glucose is leached by renal tubules, absorb back glucose by kidney proximal tubule again, but because yield is excessive, a part of glucose of that has little time to absorb enters urethra and is excluded external, therefore, do not reach due therapeutic effect.
The inventor finds in for many years oneself practice, with glucose intravenous fluid and biosynthetic human insulin intravenous fluid combination intravenous drip, treats that blood viscosity increases, the cerebral tissue blood supply insufficiency, improves arteriole and the venule blood circulation has significant curative effect; For the prevention of brain thrombosis, myocardial infarction has positive effect; For additional physical ability, improvement sleep effect is preferably arranged.
In order to solve glucose intravenous fluid and the safe and effective proportioning of biosynthetic human insulin intravenous fluid, the inventor is through repeatedly making clinical drug trial with body.Grope in test the dynamic equilibrium value of intravital glucose of people and insulin, the glucose intravenous fluid 1000ml that is about sugar content 10% is equipped with 8～12lU (iu is hereinafter to be referred as lU) biosynthetic human insulin intravenous fluid.Therefore, the intravenous fluid that the treatment blood viscosity that the inventor provides increases, the pharmaceutical composition of cerebral tissue blood supply insufficiency is the glucose intravenous fluid and the biosynthetic human insulin intravenous fluid is made into, its proportioning are that the glucose intravenous fluid 1000ml of sugar content 10% is equipped with 8～12lU biosynthetic human insulin intravenous fluid.
Optimum ratio in this scope is: with sugar content is that 10% glucose intravenous fluid 1000ml is equipped with 10lU biosynthetic human insulin intravenous fluid, makes up a prescription before facing transfusion.
The treatment blood viscosity increases, the medicine of two kinds of diseases of cerebral tissue blood supply insufficiency in order like clockwork biosynthetic human insulin intravenous fluid and glucose intravenous fluid to be made into, inventor's specialized designs " micro-measurement syringe ", and applied for utility model patent No. 201120193160.4.The using method and the principle thereof of " micro-measurement syringe " are: take off protective cover, medicine is sent into bottle rack; Take out syringe needle, be inserted on the needle holder of medicine bottle bottleneck, take off needle cap then; The rotation metering knob makes it aim at the scale that needs, syringe needle is thrust in the glucose intravenous fluid bottle, because metering knob and clutch post are reverse thread, the administration space is withdrawed from dextrorotation, promote pushing ram, the spacer of pushing ram pushes the rubber piston of medicine bottle, just required biosynthetic human insulin intravenous fluid can be injected in the glucose intravenous fluid bottle, and blood viscosity increases in order to treat, two kinds of diseases of cerebral tissue blood supply insufficiency.This has just solved the injection problem of micro-measurement medicine, and accurate measurement, and is easy to use, simple in structure, cheap.
The inventor points out that commercially available biosynthetic human insulin injection must lucifuge preservation under 2 ℃～8 ℃ conditions.
The usage and dosage of aforementioned pharmaceutical compositions, also be that the inventor obtains through repeatedly making clinical drug trial with body, usage and dosage is safely and effectively: the glucose intravenous fluid with two bottles of 10%500ml on the one, every bottle is injected 5lU biosynthetic human insulin intravenous fluid, intravenous drip, 10 days courses of treatment, be separated by between two courses of treatment and treated in 60 days a course of treatment.
Join the biosynthetic human insulin intravenous fluid through the glucose intravenous fluid, intravenous drip, carrying out the individual drugs clinical trial finds, according to intravital glucose and the administration of insulin biochemistry rule, the function that increases energy to body is not only arranged, competent energy also can impel lung, spleen, the heart, intestinal, brain and vascular endothelial cell to synthesize AF-III antithrombase, and the function that reduces blood viscosity is arranged.Simultaneously, glycometabolic intermediate material galactose and protein synthesis glycoprotein, promising body replenishes the function of blood plasma.Before the treatment, in the treatment, the hemorheology test report that the treatment back is done in inspection center of the attached institute of your doctor.The result of individual drugs clinical trial matches with the hemorheology test report, has confirmed that all this pharmaceutical composition is safely and effectively.
Use the points for attention of aforementioned pharmaceutical compositions to be: 1. to forbid the known medicine that the degrade insulin composition is arranged during the treatment, forbid to drink the beverage that contains alcoholic ingredient,, reduce or the forfeiture insulin function because of ethanol can cause protein denaturation.2. transfusion time should be chosen in blood glucose peak period intravenous drip in early a hour after the meal, detect blood glucose, blood sugar test value after the transfusion immediately as being lower than below the 5.0mmol/L or the hypoglycemic reaction sensation being arranged, add water with the 30g oral glucose takes, lay up 10 minutes, treat that but intestinal begins to absorb behind the glucose just out-of-bed activity, prevents hypoglycemic reaction.
The present invention is the use that combines of two kinds of common drugs, can treat that blood viscosity increases, two kinds of diseases of cerebral tissue blood supply insufficiency.This pharmaceutical composition is for human body, has to have no adverse reaction, and has no side effect safe and reliable advantage; Because the structure of biosynthetic human insulin intravenous fluid and the insulin structure of human endocrine are identical, so there is not anaphylaxis, can relievedly use.This pharmaceutical composition is adapted to treat cerebral blood supply insufficiency, the various symptoms that blood viscosity increases and above-mentioned pathological state causes, and the initial stage hypertension that causes as cerebral vasospasm, insomnia prevents that cerebral thrombosis etc. from also having curative effect preferably.
Description of drawings
Fig. 1 is micro-measurement syringe construction figure.1 is protective cover among the figure, and 2 is needle tubing, and 3 is bottle rack, and 4 is medicine bottle, and 5 is spacer, and 6 is sleeve pipe, and 7 is pushing ram, and 8 are the clutch post, and 9 is left-handed nut, and 10 is metering knob, and 11 is reference column, and 12 is gear, and 13 is back-moving spring.
The specific embodiment:
Following examples have illustrated the using method and the effect of this pharmaceutical composition.
Embodiment 1 usefulness micro-measurement syringe injects the bottle of glucose intravenous fluid with the biosynthetic human insulin intravenous fluid, be made into behind the medicine continuously the infusion days and the course of treatment at interval the natural law clinical trial following performance is arranged:
With sugar content is that 10% glucose intravenous fluid 1000ml is equipped with 7lU biosynthetic human insulin intravenous fluid, intravenous drip in first day does not have untoward reaction, and the hyperglycemia reaction is arranged after the intravenous drip in second day, and showing as kidney has the sense of expanding, blood pressure slightly raises, and continues 3 hours transference cures.With sugar content is that 10% glucose intravenous fluid 1000ml is equipped with 13lU biosynthetic human insulin intravenous fluid, and hypoglycemic reaction is arranged after the intravenous drip, shows as cardiopalmus, be in a cold sweat, malaise adds water with the 30g oral glucose and takes, transference cure after several minutes.
With sugar content is that 10% glucose intravenous fluid 1000ml is equipped with 10lU biosynthetic human insulin intravenous fluid, untoward reaction did not appear in 12 days in continuous intravenous infusion, the inventor analyzes, and this proportioning should be identical with insulin dynamic equilibrium value with glucose in the human body, and using value is arranged.But, intravenous drip the 13rd day, the back 6 hours blood pressures of infusing sharply raise suddenly, be up to 200/120mmHg, prove that the continuous use natural law has exceeded the safe medication scope, blood pressure of detection in 15 minutes, souning out with nifedipine and metoprolol and to take medicine, blood pressure recovers normal after 2 hours.
Carry out test second course of treatment after 30 days, intravenous drip the 9th day and the 10th day has the sensation of gastric peristalsis quickening after the transfusion, and food-intake obviously increases, and then is separated by to carry out clinical drug trial in 60 days and untoward reaction do not occur.
Embodiment 2 is according to the clinical drug trial result, selecting sugar content for use is that 10% glucose intravenous fluid 1000ml is equipped with 10lU biosynthetic human insulin intravenous fluid, the biosynthetic human insulin intravenous fluid is injected the bottle of glucose intravenous fluid with the micro-measurement syringe.This is dosage once-a-day, 10 days courses of treatment, obtains following curative effect:
First intravenous drip course of treatment the 5th day, complexion is little red by little blue or green commentaries on classics, intravenous drip the 7th day, gastrointestinal has recovered digestive and absorptive functions (can hear and digest sound with cry), day by day increase the length of one's sleep, the estazolam that must obey 2 1mg before the sleep every day, the alprazolam of 2 1mg, the promethazine hydrochloride of 2 25mg could be fallen asleep, and the clothes sleeping pill reduces half after first course of treatment.
After second course of treatment, the promethazine hydrochloride of 1 25mg of clothes just can be fallen asleep.
After the 3rd course of treatment, the estazolam of 1 1mg of clothes just can be fallen asleep.
The 4th intravenous drip course of treatment the 6th day, the estazolam of 1 1mg of clothes has been slept 10 hours, and the back of getting up is dizzy, and the excessive sensation of clothes sleeping pill is arranged, and insomnia and constipation symptom disappear simultaneously, have thoroughly broken away from the sleeping pill of obeying 17 years.
The hemorheology test report contrast that before first course of therapy and treatment back is done, treatment back than treatment before whole blood viscosity lowly cut, in cut, height cuts a little less than the reference normal value, report prompting blood viscosity is normal, the pathological state disappearance that packed cell volume raises.
Hemorheology test report [], [two] and [three] that hospital provides have illustrated its effect.
Claims (2)
- The treatment blood viscosity increase, the pharmaceutical composition of cerebral tissue blood supply insufficiency, it is characterized in that this pharmaceutical composition is the intravenous fluid that glucose intravenous fluid and biosynthetic human insulin intravenous fluid are made into, its proportioning is that the glucose intravenous fluid 1000ml of sugar content 10% is equipped with 8～12lU biosynthetic human insulin intravenous fluid.
- 2. as claimed in claim 1ly it is characterized in that this pharmaceutical composition is is that 10% glucose intravenous fluid 1000ml is equipped with the intravenous fluid that the 10lU biosynthetic human insulin is made into sugar content.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101584514A CN102228682A (en) | 2011-06-14 | 2011-06-14 | Medicinal composition for treating increased blood viscosity and blood supply insufficiency of brain tissues |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101584514A CN102228682A (en) | 2011-06-14 | 2011-06-14 | Medicinal composition for treating increased blood viscosity and blood supply insufficiency of brain tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102228682A true CN102228682A (en) | 2011-11-02 |
Family
ID=44841314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101584514A Pending CN102228682A (en) | 2011-06-14 | 2011-06-14 | Medicinal composition for treating increased blood viscosity and blood supply insufficiency of brain tissues |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102228682A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113367885A (en) * | 2020-03-10 | 2021-09-10 | 成都普道尔生物科技有限公司 | Glaucoma drainage tube, material thereof and implantation device |
-
2011
- 2011-06-14 CN CN2011101584514A patent/CN102228682A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113367885A (en) * | 2020-03-10 | 2021-09-10 | 成都普道尔生物科技有限公司 | Glaucoma drainage tube, material thereof and implantation device |
| CN113367885B (en) * | 2020-03-10 | 2022-07-29 | 成都米戈思医疗技术有限公司 | Glaucoma drainage tube, material thereof and implantation device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100540022C (en) | A kind of Chinese medicine preparation for the treatment of early diabetic retinopathy | |
| CN108524673A (en) | A kind of Chinese medicine composition and its application | |
| CN103417846A (en) | Hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| CN1817354B (en) | Injection of manchurian wildginge and astragalus root and its preparing method | |
| CN102228682A (en) | Medicinal composition for treating increased blood viscosity and blood supply insufficiency of brain tissues | |
| CN110251591A (en) | A kind of pharmaceutical composition and its preparation method and application that aided blood pressure-lowering is hypoglycemic | |
| CN102940677B (en) | Medicine composition for treating diabetic foot | |
| CN100556440C (en) | A kind of Chinese medicine pharmaceutical composition for the treatment of diabetes and its production and application | |
| CN102940743B (en) | Medicine composition for treating diabetic foot | |
| CN1879640A (en) | Ginsenoside Rh2Ck and Rg3Application in increasing myocardial contractility | |
| CN103599254B (en) | Chinese medicinal composition for diabetes | |
| CN101375847A (en) | Medicament composition with dehydration and diuresis functions | |
| CN101653474B (en) | Medicine for treating hemorrhoid and its preparing process | |
| CN102940671B (en) | Medicine composition for treating diabetic foot | |
| CN103751410A (en) | Health care wine for nourishing the liver, improving vision, tonifying essence and nourishing kidney | |
| CN101612391A (en) | A kind of pharmaceutical composition of Cure for insomnia disease | |
| CN101406666B (en) | Chinese medicine for treating coronary heart disease and angina pectoris, and preparation method and use thereof | |
| CN105055892A (en) | Pharmaceutical composition for treating pulmonary heart disease | |
| CN1425412A (en) | Compound oral thrombolytic preparation and its preparing method | |
| CN113797286A (en) | Traditional Chinese medicine formula for treating hypertension, hyperlipidemia, hyperglycemia and hyperuricemia | |
| CN101081264A (en) | Chinese medicine for treating hypertension and method for making same | |
| CN104906495A (en) | Hypertension symptom improvement medicine mainly using rhodiola rosea | |
| CN105053307A (en) | Traditional Chinese medicine health tea | |
| CN104606578A (en) | Traditional Chinese medicine composition for treating superficial thrombophebitis caused by medicine | |
| CN104491764A (en) | Medicine composition used for treating anus eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111102 |